Sorrento Therapeutics, Inc.
SRNE
$0.001
-$0.0031-75.61%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -95.11M | -139.62M | -223.69M | -89.58M | -218.76M |
| Total Depreciation and Amortization | 3.59M | 3.62M | 3.35M | 3.36M | 3.24M |
| Total Amortization of Deferred Charges | 0.00 | 5.25M | -- | -- | -- |
| Total Other Non-Cash Items | 2.41M | 50.64M | 108.44M | 141.00K | 128.83M |
| Change in Net Operating Assets | 33.45M | 30.64M | 43.57M | 24.91M | 5.71M |
| Cash from Operations | -55.66M | -49.46M | -68.34M | -61.17M | -80.99M |
| Capital Expenditure | -140.00K | -86.00K | -4.52M | -3.84M | -2.71M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 7.81M | -4.26M | 977.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 1.77M | -8.32M | -- | -- |
| Cash from Investing | -140.00K | 1.68M | -5.03M | -8.09M | -1.73M |
| Total Debt Issued | 76.21M | 41.78M | 886.00K | 41.47M | -28.00K |
| Total Debt Repaid | -1.73M | -3.56M | -35.53M | -41.44M | -63.02M |
| Issuance of Common Stock | -- | 22.97M | 62.67M | 71.48M | 104.82M |
| Repurchase of Common Stock | -1.44M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -11.00K | -- | -- | -- | -- |
| Other Financing Activities | 15.79M | -- | -2.95M | -- | -- |
| Cash from Financing | 88.81M | 61.20M | 25.08M | 71.50M | 41.77M |
| Foreign Exchange rate Adjustments | -920.00K | 600.00K | 1.24M | -1.89M | -616.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 32.09M | 14.02M | -47.05M | 341.00K | -41.56M |